Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide ... Ro states that this whole process can take a week. PlushCare is another ...

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

Fat metabolism is a fascinating process and essential for human survival. It involves the digestion, absorption, transportation and utilization of lipids as a source of energy or as an energy reserve.

NLS Pharmaceutics Ltd. ("NLS") , a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders ...

This article explores methods to enhance efficiency in the drug discovery and development pipeline, focusing on optimizing ...